Abstract
Cryptococcus neoformans is the major etiologic agent of cryptococcosis. Although usually a pulmonary pathogen, C. neoformans frequently disseminates to the central nervous system. The organism has emerged as a primary cause of opportunistic infections associated with Acquired Immunodeficiency Syndrome (AIDS). Up to 9% of patients with AIDS or AIDS related complex have been reported to have cryptococcosis (Dismukes, 1988). The Centers for Disease Control, U.S.A. (CDC), projects that 390,000 to 480,000 cases of AIDS will be reported by the end of 1993. The CDC-AIDS Program, reported 28,406 cases of AIDS in the U.S.A. for 1988; 1632 (5.75%) of that number had cryptococcosis. CDC expects approximately 52,000 new cases of AIDS to be reported in 1990. If the current trend of presentation of cryptococcosis in AIDS patients continues in 1990, then the U.S.A. can expect about 3,000 new cases of cryptococcosis associated with AIDS in 1990.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bhattacharjee AK, Bennett JE, Glaudemans CPJ (1984) Capsular polysaccharides of Cryptococcus neofommans. Rev Infect Dis 6: 619–624
Bhattacharjee AK, Kwon-Chung KF, Glaudemans CPJ (1981) Capsular polysaccharides from a parent strain and from a possible mutant strain of C. neofonnans serotype A. Carbohydr Res 95: 237–247
Bulmer GS, Sans MD (1967) Cryptococcus neofonnans II: Phagocytosis by human leukocytes. J Bact 94: 1480–1483
Bulmer GS, Sans MD (1968) Cryptococcus neofonnans III. Inhibition of phagocytosis. J Bact 95: 5–8
Cherniak R (1988) Polysaccharides of Cryptococcus neofonnans. In: McGinnis MR (ed) Topics in Med Mycology, vol II, Springer Verlag, New York, pp 40–54
Cherniak R, Morris LC, Anderson BA, Meyer SA (1991) Facilitated isolation, purification and analysis of glucuronoxylomannan of Cryptococcus neoformans. Infect Immun 59: (in press)
Cherniak R, Jones RG, Reiss E (1988a) Structure determination of Cryptococcus neoformans serotype Avariant glucuronoxylomannan by 13C-NMR spectroscopy. Carbohydr Res 172: 113–138
Cherniak R, Jones RG, Slodki ME (1988b) Type specific polysaccharides of Cryptococcus neoformans. N.M.R. spectral study of glucuronoxylomannan chemically derived from Tremella mesenterica exopolysaccharide. Carbohydr Res 181: 1–13
Cherniak R, Reiss E, Slodki ME, Plattner RD, Blumer SO (1980) Structure and antigenic activity of the capsular polysaccharide from Cryptococcus neoformans serotype A. Mol Immunol 17: 1025–1032
Cherniak RD, Reiss E, Turner SH (1982) A galactoxylomannan antigen of Cryptococcus neoformans serotype A. Carbohydr Res 103: 239–250
Dismukes WE (1988) Cryptococcal meningitis in patients with AIDS. J Infect Dis 157: 624–628
Evans EE, Kessel JF (1951) A qualitative analysis of capsular polysaccharides from Cryptococcus neoformans by filter paper chromatography. Science 114: 10–11
Ikeda R, Shinoda R, Fukazawa Y, Kaufman L (1982) Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J Clin Microbiol 16: 22–29
James PG, Cherniak R, Jones RG (1989) Heterogeneity of the galactoxylomannan of Cryptococcus neoformans. American Society for Microbiology 89: 475
James PJ, Cherniak R, Jones RG (1990) Cell-wall glucans of Cryptococcus neofonnans Cap 67. Carbohydr Res 198: 23–38
Kozel TR, Gulley WF, Cazin JJ (1977) Immune response to Cryptococcus neofonnans soluble polysaccharide: Immunological unresponsiveness. Infect Immun 18: 701–707
Merrifield EH, Stephens AM (1980) Structural investigations of two capsular polysaccharides from Cryptococcus neoformans. Carbohydr Res 86: 69–76
Murphy JW, Cozad GC (1972) Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun 5: 896–901
Reiss E, Cherniak R, Eby R, Kaufman L (1984) Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptococcus neoformans. Diag Immunol 2: 109–115
Turner SI-I, Cherniak R (1991) Glucuronoxylomannan from Cryptococcus neoformans Serotype B: Structural analysis by gas-liquid chromatography-mass spectrometry and 3C-Nuclear magnetic resonance spectroscopy. Carbohydr Res (in press)
Turner SH, Cherniak R, Reiss E (1984) Fractionation and characterization of galactoxylomannan from Cryptococcus neofonnans. Carbohydr Res 125: 343–349
Turner SH, Cherniak R, Reiss E (1990) 13C-N.m.r. spectroscopic evidence for variability in the structure of the glucuronoxylomannan of Cryptococcus neofonnans serotype A strains. American Society for Microbiology 90: 426
van de Moer A, Salhi SL, Cherniak R, Pau B, Garrigues ML, Bastide JM (1990) An anti-Cryptococcus neofonnans monoclonal antibody directed against galactoxylomannan. Res Immunol 141: 33–42
Wilson DE, Bennett JE, Bailey JW (1968) Serologic grouping of Cryptococcus neoformans. Proc Soc Exp Biol Med 127: 820–823
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Turner, S.H., Cherniak, R. (1991). Multiplicity in the Structure of the Glucuronoxylomannan of Cryptococcus Neoformans . In: Latgé, J.P., Boucias, D. (eds) Fungal Cell Wall and Immune Response. NATO ASI Series, vol 53. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76074-7_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-76074-7_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-76076-1
Online ISBN: 978-3-642-76074-7
eBook Packages: Springer Book Archive